54509-63-6Relevant articles and documents
LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE
-
Paragraph 0229; 0231, (2018/03/01)
Shown are a liquid crystal compound satisfying at least one of physical properties such as high stability to heat and light, a high clearing point (or high maximum temperature), low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and satisfactory compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition. A compound is represented by formula (1), a liquid crystal composition contains the compound, or the like.
LIQUID CRYSTALLINE COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, AND LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT EACH COMPRISING SAME
-
Page/Page column 37-38, (2012/01/11)
The invention provides a liquid crystal compound having general physical properties necessary for a liquid crystal compound, that is to say, stability to heat, light or the like, a small viscosity, a suitable value of refractive index anisotropy, a suitable value of dielectric anisotropy, steep characteristics electro-optic characteristics, a wide temperature range of a nematic phase and an excellent compatibility with other liquid crystal compounds, and a liquid crystal compounds especially having a wide temperature range of a nematic phase. A compound represented by formula (1). For example, R1 and R2 are each independently alkyl having 1 to 9 carbons or alkenyl having 2 to 9 carbons, alkoxy having 1 to 8 carbons or alkenyloxy having 2 to 8 carbons; Q1 and Q4 are each independently fluorine or chlorine; Q2 and Q3 are each independently hydrogen, fluorine or chlorine, and one of Q2 and Q3 is hydrogen; Z is -CH2O or -COO-; and h is 1 or 2.
BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY
-
Page/Page column 65, (2010/02/10)
The invention is directed to a bi-aryl compound having a unique immunomodulating activity, a process for a preparation thereof, a pharmaceutical composition containing the same, and a method of preventing or treating disorders or diseases mediated by T lymphocytes by administering the compound to a subject in need of treatment.